Literature DB >> 21968786

Update on toxic myopathies.

F L Mastaglia1, M Needham.   

Abstract

The toxic myopathies are a clinically and pathologically diverse group of disorders that can be caused by a variety of therapeutic agents used in clinical practice, as well as various venoms and other biological toxins. The most important iatrogenic causes are the statin and fibrate cholesterol-lowering agents that can cause a severe necrotizing myopathy and acute rhabdomyolysis and myoglobinuria. The current update focuses on the mechanisms of statin myotoxicity and the importance of genetic predisposing factors for statin myopathy, as well as the recently described form of necrotizing autoimmune myopathy, which is associated with antibodies to the 3-hydroxy-3-methylglutaryl-coenzyme A reductase enzyme and is responsive to aggressive immunotherapy. Mitochondrial myopathies associated with antiretroviral agents and the pyrimidine nucleoside analogue clevudine, and recent reports of myopathies caused by ingestion of red yeast rice and toxic species of mushrooms are also discussed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21968786     DOI: 10.1007/s11910-011-0232-9

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  95 in total

1.  Myopathy associated with statin therapy.

Authors:  David Hilton-Jones
Journal:  Neuromuscul Disord       Date:  2007-09-24       Impact factor: 4.296

2.  Vitamin D insufficiency--a novel mechanism of statin-induced myalgia?

Authors:  Paul Lee; Jerry R Greenfield; Lesley V Campbell
Journal:  Clin Endocrinol (Oxf)       Date:  2008-10-16       Impact factor: 3.478

3.  Neuromuscular symptoms and elevated creatine kinase after statin withdrawal.

Authors:  Andoni Echaniz-Laguna; Michel Mohr; Christine Tranchant
Journal:  N Engl J Med       Date:  2010-02-11       Impact factor: 91.245

4.  Metabolic myopathies discovered during investigations of statin myopathy.

Authors:  Steven K Baker; Georgirene D Vladutiu; Wendy L Peltier; Paul J Isackson; Mark A Tarnopolsky
Journal:  Can J Neurol Sci       Date:  2008-03       Impact factor: 2.104

5.  The SLCO1B1*5 genetic variant is associated with statin-induced side effects.

Authors:  Deepak Voora; Svati H Shah; Ivan Spasojevic; Shazia Ali; Carol R Reed; Benjamin A Salisbury; Geoffrey S Ginsburg
Journal:  J Am Coll Cardiol       Date:  2009-10-20       Impact factor: 24.094

6.  [Polymyositis induced or associated with lipid-lowering drugs: five cases].

Authors:  A-L Fauchais; J Iba Ba; P Maurage; X Kyndt; D Bataille; E Hachulla; D Parent; V Queyrel; M Lambert; U Michon Pasturel; P-Y Hatron; P Vanhille; B Devulder
Journal:  Rev Med Interne       Date:  2004-04       Impact factor: 0.728

7.  Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.

Authors:  Chantale Simard; Paul Poirier
Journal:  Can J Cardiol       Date:  2006-02       Impact factor: 5.223

8.  Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors.

Authors:  Christopher Rowan; Allen D Brinker; Parivash Nourjah; Jennie Chang; Andrew Mosholder; Jeffrey S Barrett; Mark Avigan
Journal:  Pharmacoepidemiol Drug Saf       Date:  2009-04       Impact factor: 2.890

9.  Muscle coenzyme Q10 level in statin-related myopathy.

Authors:  Costanza Lamperti; Ali B Naini; Valeria Lucchini; Alessandro Prelle; Nereo Bresolin; Maurizio Moggio; Monica Sciacco; Petra Kaufmann; Salvatore DiMauro
Journal:  Arch Neurol       Date:  2005-11

10.  A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle.

Authors:  Reijo Laaksonen; Mikko Katajamaa; Hannu Päivä; Marko Sysi-Aho; Lilli Saarinen; Päivi Junni; Dieter Lütjohann; Joél Smet; Rudy Van Coster; Tuulikki Seppänen-Laakso; Terho Lehtimäki; Juhani Soini; Matej Oresic
Journal:  PLoS One       Date:  2006-12-20       Impact factor: 3.240

View more
  11 in total

1.  Seeking Genomic Knowledge: The Case for Clinical Restraint.

Authors:  Wylie Burke; Susan Brown Trinidad; Ellen Wright Clayton
Journal:  Hastings Law J       Date:  2013-08-01

Review 2.  Diagnosis, pathogenesis and treatment of myositis: recent advances.

Authors:  P-O Carstens; J Schmidt
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

3.  NMR evaluation of total statin content and HMG-CoA reductase inhibition in red yeast rice (Monascus spp.) food supplements.

Authors:  Dirk W Lachenmeier; Yulia B Monakhova; Thomas Kuballa; Sigrid Löbell-Behrends; Sibylle Maixner; Matthias Kohl-Himmelseher; Asja Waldner; Christian Steffen
Journal:  Chin Med       Date:  2012-03-22       Impact factor: 5.455

Review 4.  Drugs in induction and treatment of idiopathic inflammatory myopathies.

Authors:  Luca Iaccarino; Elena Bartoloni; Roberto Gerli; Alessia Alunno; Simone Barsotti; Giacomo Cafaro; Mariele Gatto; Rosaria Talarico; Alessandra Tripoli; Margherita Zen; Rossella Neri; Andrea Doria
Journal:  Auto Immun Highlights       Date:  2014-10-19

Review 5.  Elevated risk of venous thromboembolic events in patients with inflammatory myopathies.

Authors:  Michał Nowak; Katarzyna Królak-Nowak; Aleksandra Sobolewska-Włodarczyk; Jakub Fichna; Marcin Włodarczyk
Journal:  Vasc Health Risk Manag       Date:  2016-06-03

6.  Genetic Variations and Frequencies of the Two Functional Single Nucleotide Polymorphisms of SLCO1B1 in the Thai Population.

Authors:  Chalitpon Na Nakorn; Jariya Waisayarat; Charungthai Dejthevaporn; Pornpen Srisawasdi; Sansanee Wongwaisayawan; Chonlaphat Sukasem
Journal:  Front Pharmacol       Date:  2020-06-05       Impact factor: 5.810

7.  Red Yeast Rice: A Systematic Review of the Traditional Uses, Chemistry, Pharmacology, and Quality Control of an Important Chinese Folk Medicine.

Authors:  Bo Zhu; Fangyuan Qi; Jianjun Wu; Guoqing Yin; Jinwei Hua; Qiaoyan Zhang; Luping Qin
Journal:  Front Pharmacol       Date:  2019-12-02       Impact factor: 5.810

8.  Incidence, etiology, and outcomes of rhabdomyolysis in a single tertiary referral center.

Authors:  Jae-Seok Park; Min-Sook Seo; Hyo-Wook Gil; Jong-Oh Yang; Eun-Young Lee; Sae-Yong Hong
Journal:  J Korean Med Sci       Date:  2013-07-31       Impact factor: 2.153

9.  Study of Statin- and Loratadine-Induced Muscle Pain Mechanisms Using Human Skeletal Muscle Cells.

Authors:  Yat Hei Leung; Jacques Turgeon; Veronique Michaud
Journal:  Pharmaceutics       Date:  2017-10-10       Impact factor: 6.321

Review 10.  Myopathology of Adult and Paediatric Mitochondrial Diseases.

Authors:  Rahul Phadke
Journal:  J Clin Med       Date:  2017-07-04       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.